1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
136.25 USD   -4.97%
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five years
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Israel Reopens Borders To Entry By Foreign Nationals

01/17/2022 | 01:09am EDT

On January 9, 2022, Israel loosened several pandemic-related restrictions on the entry of foreign nationals. The country had previously relaxed its entry restrictions in November 2021 but re-imposed them only weeks later following the identification of the omicron variant. Under the new reopening guidelines, fully vaccinated foreign nationals, as well as some unvaccinated but recovered individuals, will be allowed to enter Israel.

Entry Eligibility for Vaccinated or Recovered Travelers

Tourists and other foreign nationals seeking to take advantage of Israel's relaxed entry guidelines will have to comply with strict documentation, testing, and quarantine requirements established by the Israeli Ministry of Health. Specifically, travelers will need to apply for a Green Pass before arrival, demonstrating compliance with the following requirements:

<ul
  • Travelers who received the Pfizer-BioNTech vaccine must demonstrate receipt of the second or third dose no less than 7 days and no more than 6 months before arrival.
  • Travelers who received the Moderna or AstraZeneca vaccine must demonstrate receipt of the second or third dose no less than 14 days and no more than 6 months before arrival.
  • Travelers who have received only one dose of an approved vaccine between January 6 and January 18, 2022, will be eligible for temporary Green Pass for 30 days, unless they have been exposed to a confirmed COVID-19 patient.
  • Certain unvaccinated travelers who can demonstrate natural recovery from COVID-19 will also be allowed entry, under the following guidelines:

    <ul
  • Travelers who are unvaccinated but hold a certificate of recovery showing a positive PCR test result are eligible for a Green Pass valid for up 6 months from the date of the last certificate of recovery.
  • Travelers who have recovered from COVID-19 and also received one dose of an approved vaccine before or after recover are eligible for a Green Pass valid through March 31, 2022.
  • Travelers who have recovered from COVID-19 and subsequently tested positive on a serological test, who were not vaccinated before testing, and who subsequently received at least one dose of an approved vaccine after testing are eligible for a Green Pass valid through December 31, 2022.
  • Children up to 12 years and 3 months of age are eligible for a Green Pass valid until March 31, 2022, or until they reach the age of 12 years and 3 months, whichever is later.
  • Children up to 12 years and 3 months of age who test positive on a serological test are eligible for a Green Pass valid through December 31, 2022 or until they reach the age of 12 years and 3 months, whichever is later.
  • Testing and Quarantine Requirements

    All travelers, regardless of vaccination status, must comply with the following testing and quarantine requirements in order to enter Israel:

    <ul
  • Take a PCR test in the 72 hours before the flight to Israel, or take a rapid antigen test in the 24 hours before the flight (At-home tests are not acceptable.) Travelers must present an official document showing their test results.
  • Fill out the Entry Statement Form within 48 hours prior to departure. Upon completion of the form, travelers will receive a link to pay in advance for a PCR test upon arrival.
  • Take a PCR test upon arrival in Israel.
  • Isolate for 24 hours or until a negative result is received from the PCR arrival test. Additional isolation requirements may apply in certain cases.
  • Recognized Vaccines

    For purposes of the entry restrictions, Israel will accept vaccination with COVID-19 vaccines approved by the World Health Organization, including:

    <ul
  • Pfizer-BioNTech
  • Moderna
  • Johnson & Johnson
  • AstraZeneca
  • Sinovac
  • SinoPharm
  • Serum Institute of India
  • Bharat Biotech
  • Immunization with the Sputnik V vaccine are also recognized. However, additional restrictions may apply, including isolation and testing requirements.

    Please continue to follow updates on our blog, The Mobile Workforce.

    Visit us at mayerbrown.com

    Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe - Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

    © Copyright 2020. The Mayer Brown Practices. All rights reserved.

    This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

    Mr Paul Justas Sarauskas
    Mayer Brown
    71 S. Wacker Dr.
    Chicago
    IL 60606
    UNITED STATES
    Tel: 3127820600
    Fax: 3127017711
    E-mail: Mnoonan@mayerbrown.com
    URL: www.mayerbrown.com

    © Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

    Stocks mentioned in the article
    ChangeLast1st jan.
    ASTRAZENECA PLC 2.38% 10494 Delayed Quote.20.93%
    MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
    All news about MODERNA, INC.
    05/19EU health regulator backs using AstraZeneca COVID shot as booster
    RE
    05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
    MT
    05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
    RE
    05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
    MT
    05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
    MT
    05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
    RE
    05/17TRANSCRIPT : Moderna, Inc. - Special Call
    CI
    05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
    DJ
    05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhi..
    AQ
    05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
    MT
    More news
    Analyst Recommendations on MODERNA, INC.
    More recommendations
    Financials (USD)
    Sales 2022 22 069 M - -
    Net income 2022 11 501 M - -
    Net cash 2022 18 081 M - -
    P/E ratio 2022 5,01x
    Yield 2022 -
    Capitalization 54 195 M 54 195 M -
    EV / Sales 2022 1,64x
    EV / Sales 2023 3,33x
    Nbr of Employees 2 700
    Free-Float 90,6%
    Chart MODERNA, INC.
    Duration : Period :
    Moderna, Inc. Technical Analysis Chart | MarketScreener
    Full-screen chart
    Technical analysis trends MODERNA, INC.
    Short TermMid-TermLong Term
    TrendsNeutralBearishBearish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 19
    Last Close Price 136,25 $
    Average target price 212,69 $
    Spread / Average Target 56,1%
    EPS Revisions
    Managers and Directors
    Stéphane Bancel Chief Executive Officer & Director
    Stephen Hoge President
    David W. Meline Chief Financial Officer
    Noubar B. Afeyan Chairman
    Juan Andres Chief Technical Operations & Quality Officer
    Sector and Competitors
    1st jan.Capi. (M$)
    MODERNA, INC.-46.35%54 195
    LONZA GROUP AG-27.84%41 796
    IQVIA HOLDINGS INC.-28.46%38 202
    SEAGEN INC.-9.68%25 704
    ICON PUBLIC LIMITED COMPANY-30.22%17 567
    ALNYLAM PHARMACEUTICALS, INC.-23.72%15 980